Davorka L. Tomic
Eysins, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Journal: The Lancet. Neurology
Published: May 16, 2024
Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 04, 2024
Effect of Evobrutinib on Slowly Expanding Lesion Volume in Relapsing Multiple Sclerosis: A Post Hoc Analysis of a Phase 2 Trial.
Journal: Neurology
Published: February 09, 2024
Antibody response to SARS-CoV-2 vaccines in patients with relapsing multiple sclerosis treated with evobrutinib: A Bruton's tyrosine kinase inhibitor.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 26, 2023
A plain language summary of what clinical studies can tell us about the safety of evobrutinib - a potential treatment for multiple sclerosis.
Journal: Neurodegenerative disease management
Published: June 22, 2023
Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Journal: Neurology
Published: October 03, 2022
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 05, 2022
Safety of Fingolimod in Patients with Multiple Sclerosis Switched from Natalizumab: Results from TRANSITION-A 2-Year, Multicenter, Observational, Cohort Study.
Journal: Brain sciences
Published: November 29, 2021
Baseline characteristics and effects of fingolimod on cognitive performance in patients with relapsing-remitting multiple sclerosis.
Journal: European journal of neurology
Published: May 19, 2021
Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: March 26, 2021
Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 18, 2020
Last Updated: 09/26/2026